EUVIMEDEUVIMED entdecken
Crossref

Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation

Alireza Seyedabadi, Pejman Porouhan, Hamid-Reza Sadoughi, Ruhollah Ghahramani-Asl

Radiation Protection Dosimetry · 2025

DOI: 10.1093/rpd/ncaf054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Protection Dosimetry, 2025. Verfasst von Alireza Seyedabadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Sabzevar University of Medical Sciences, Shohadaye Hasteiee Blvd, Sabzevar, 9617913112, Iran. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Radiopharmaceuticals. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Sabzevar University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent developments in targeted radiopharmaceuticals offer promising options for diagnosis and treatment by specifically targeting the overexpressed somatostatin receptors in neuroendocrine tumors (NETs). This study aims to assess the radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of NETs. Four patients were selected for imaging using 177Lu-octreotide or DOTATATE via Single photon emission computed tomography/Computed tomography (SPECT/CT). The absorbed doses were calculated employing the Medical Internal Radiation Dose (MIRD) method and S-value tables associated with 177Lu, utilizing the GEANT4 Application for Tomographic Emission (GATE) calculation code. The mean percentage differences in the S-values between the GATE and IDAC2.1 calculation methods were −0.7 for S (Spleen→Spleen), −3.5 for S (Kidneys→Kidneys), and 4.9 for S (Liver→Liver). The mean absorbed doses from the GATE were 0.076, 0.20, 0.29, and 0.47 mGy/MBq for the liver, kidneys, spleen, and tumors, respectively. Assessment of the results obtained from the GATE code as a voxel-level dose calculation tool in non-uniform media showed that 177Lu-DOTATATE may provide beneficial therapeutic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideOrganometallic CompoundsRadiopharmaceuticalsRadioisotopesHumansSingle Photon Emission Computed Tomography Computed TomographyMaleFemaleRadiotherapy DosageComputer SimulationMiddle AgedRadiation DosageRadiotherapy Planning, Computer-Assisted

Substanzen

Octreotidelutetium Lu 177 dotatateOrganometallic CompoundsRadiopharmaceuticalsRadioisotopes

Autor:innen und Institutionen

  • Student Research Committee, Sabzevar University of Medical Sciences, Shohadaye Hasteiee Blvd, Sabzevar, 9617913112, Iran.
  • Department of Radiation Oncology, Vasee Hospital, Sabzevar University of Medical Sciences, Shohadaye Hasteiee Blvd, Sabzevar, 9617747431, Iran.
  • Department of Medical Physics and Radiology, Faculty of Medicine, North Khorasan University of Medical Sciences, Dowlat Blvd, Bojnurd, 9414975516, Iran.
  • Department of Medical Physics and Radiological Sciences, Faculty of Paramedicine, Sabzevar University of Medical Sciences, Shohadaye Hasteiee Blvd, Sabzevar, 961791311, Iran.
  • Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Shohadaye Hasteiee Blvd, Sabzevar, 9617913112, Iran.

Förderung

  • Sabzevar University of Medical Sciences

Zitieren

APA

Seyedabadi, A., Porouhan, P., Sadoughi, H. R., & Ghahramani-Asl, R. (2025). Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation. Radiation Protection Dosimetry. https://doi.org/10.1093/rpd/ncaf054

Vancouver

Seyedabadi A, Porouhan P, Sadoughi HR, Ghahramani-Asl R. Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation. Radiation Protection Dosimetry. 2025. doi:10.1093/rpd/ncaf054

BibTeX
@article{Seyedabadi2025,
  author = {Seyedabadi, Alireza and Porouhan, Pejman and Sadoughi, Hamid-Reza and Ghahramani-Asl, Ruhollah},
  title = {Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation},
  journal = {Radiation Protection Dosimetry},
  year = {2025},
  doi = {10.1093/rpd/ncaf054}
}
Kostenlos starten →